PF-07321332

• CAS: 2628280-40-8
• Catalog Number: ACM2628280408
• Category: Inhibitors
• Molecular Weight: 499.54
• Molecular Formula: C23H32F3N5O4
• Description: Nirmatrelvir, also known as PF-07321332 (brand name: Paxlovid), is an orally bioavailable 3C-like protease (3CLPRO) inhibitor and SARS-CoV-2 Mpro inhibitor. This drug is being investigated for safety, tolerability, and pharmacokinetics before moving on to studies of efficacy in the treatment or prophylaxis of COVID-19. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. PF-07321332 is an oral COVID-19 antiviral clinical candidate. By inhibiting the main protease, PF-07321332 prevents the virus from cleaving long protein chains into the parts it needs to reproduce itself.
• Synonyms: Nirmatrelvir; PF-07321332; PF 07321332; PF07321332; brand name Paxlovid
• IUPAC Name: (1R,2S,5S)-N-((S)-1-cyano-2-((S)-2-oxopyrrolidin-3-yl)ethyl)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• Canonical SMILES: [H][C@]12CN([C@H](C(=O)N[C@@H](C[C@]3([H])CCNC3=O)C#N)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C
• InChI: InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
• InChI Key: LIENCHBZNNMNKG-OJFNHCPVSA-N
• Solubility: To be determined
• Appearance: Solid powder
• Shelf Life: >2 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Biological Target: PF-07321332 targets the SARS-CoV-2 virus and can be used for COVID-19 reseacrch. IC50: 3CLPRO
• Drug Formulation: To be determined
• Elemental Analysis: C, 55.30; H, 6.46; F, 11.41; N, 14.02; O, 12.81
• Exact Mass: 499.2406
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: The in vitro antiviral activity of PF-332 against the four main SARS-CoV-2 VoC was first assessed in Vero E6 and A549 (overexpressing ACE2/TMPRSS2) cells, the EC50 values obtained were between 70 and 280 nM. The antiviral effect of PF-332 was next assessed in primary human airway epithelial cell (HAEC) [that had been fully differentiated into an air-liquid (ALI) culture system] that were infected with the alpha variant (B.1.1.7). When added to the culture medium at the basolateral site of the ALI's 1 h before infection (at the topical site) PF-332 (at 1 µM) completely inhibited viral replication for the entire duration of the experiment. At a concentration of 0.1 µM the inhibition was transient.; Reference: Nat Commun. 2022 Feb 15;13(1):719. https://pubmed.ncbi.nlm.nih.gov/35169114/
• In Vivo Activity: Female hamsters (6-8 weeks) were intranasally infected with the SARS-CoV2 beta variant (lineage B.1.351) and were orally treated with PF-332 [either at 125 or 250 mg/kg/dose, twice daily (BID)] or the vehicle (i.e., the control group) for four consecutive days whereby treatment was initiated immediately before infection. Treatment resulted in a dose-dependent reduction of viral RNA copies in lung tissue; i.e., 1.1 log10 (P = 0.0007) and 5.8 log10 (P < 0.0001) reduction in, respectively, the 125 and 250 mg/kg, BID treatment groups. Likewise the 125 mg/kg BID dose resulted in a 0.7 log10 (P = 0.03) reduction in lung infectious virus titers and treatment with 250 mg/kg BID resulted in undetectable infectious virus levels in the lungs in all the treated animals (4.4 log10 reduction, P < 0.0001). No clinical signs of adverse effects were observed in any of the PF-332-treated groups. Treatment also markedly improved virus-induced lung pathology, in particular in the 250 mg/kg BID dose whereby the lung pathology score was (in 11 out of 12 animals) comparable to the baseline score of untreated, non-infected hamsters (P < 0.0001).; Reference: Nat Commun. 2022 Feb 15;13(1):719. https://pubmed.ncbi.nlm.nih.gov/35169114/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).